Carvedilol blockade of rat myocardial α1-adrenoceptors

European Journal of Pharmacology

Volumn 481, Issue 1, 2003, Pages 83-89

  Qvigstad, Eirik ^a   Osnes, Jan Bjørn ^a   Sandnes, Dagny ^a   Schiander, Iwona ^a   Bøkenes, Janny ^b   Sjaastad, Ivar ^b   Skomedal, Tor ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carvedilol; Myocardium, rat; 1 Adrenoceptor; Adrenoceptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARVEDILOL; INOTROPIC AGENT; ISOPRENALINE; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; RADIOLIGAND; TIMOLOL;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART LEFT VENTRICLE; HEART MUSCLE; HEART PAPILLARY MUSCLE; INOTROPISM; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0344153881     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.001     Document Type: Article

References (37)

1. Andersen G.O., Enger M., Thoresen G.H., Skomedal T., Osnes J.B. Alpha1-adrenergic activation of myocardial Na-K-2Cl cotransport involving mitogen-activated protein kinase. Am. J. Physiol. 275:1998;H641-H652.
2. Ariëns E.J., Simonis A.M., van Rossum J.M. Drug-receptor interaction: Interaction of one or more drugs with one receptor system. Ariëns E.J. Mol. Pharmacol. 1:1964;119-286 Academic Press, New York.
3. Bristow M.R., Larrabee P., Minobe W., Roden R., Skerl L., Klein J., Handwerger D., Port J.D., Muller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 19(Suppl. 1):1992;S68-S80.
4. Brixius K., Bundkirchen A., Bolck B., Mehlhorn U., Schwinger R.H. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol. 133:2001;1330-1338.
5. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
6. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 357:2001;1385-1390.
7. Deng X.F., Chemtob S., Varma D.R. Characterization of alpha 1D-adrenoceptor subtype in rat myocardium, aorta and other tissues. Br. J. Pharmacol. 119:1996;269-276.
8. Dunn C.J., Lea A.P., Wagstaff A.J. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 54:1997;161-185.
9. Eichhorn E.J., Bristow M.R. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr. Control Trials, Cardiovasc. Med. 2:2001;20-23.
10. Iyengar R., Abramowitz J., Bordelon-Riser M., Blume A.J., Birnbaumer L. Regulation of hormone-receptor coupling to adenylyl cyclase. Effects of GTP and GDP. J. Biol. Chem. 255:1980;10312-10321.
11. Maack C., Cremers B., Flesch M., Hoper A., Sudkamp M., Bohm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. J. Pharmacol. 130:2000;1131-1139.
12. Metra M., Nardi M., Giubbini R., Dei C.L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 24:1994;1678-1687.
13. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Dei C.L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 102:2000;546-551.
14. Michel M.C., Hanft G., Gross G. Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. Br. J. Pharmacol. 111:1994;533-538.
15. Michel M.C., Kenny B., Schwinn D.A. Classification of alpha 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;1-10.
16. Milano C.A., Dolber P.C., Rockman H.A., Bond R.A., Venable M.E., Allen L.F., Lefkowitz R.J. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 91:1994;10109-10113.
17. Monopoli A., Forlani A., Bevilacqua M., Vago T., Norbiato G., Bertora P., Biglioli P., Alamanni F., Ongini E. Interaction of selected vasodilating beta-blockers with adrenergic receptors in human cardiovascular tissues. J. Cardiovasc. Pharmacol. 14:1989;114-120.
18. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., Ruffolo R.R. Jr. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 39:1989;327-336.
19. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., Ruffolo R.R. Jr. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1:1989;265-270.
20. Nichols A.J., Gellai M., Ruffolo R.R. Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam. Clin. Pharmacol. 5:1991;25-38.
21. Ohlstein E.H., Douglas S.A., Sung C.P., Yue T.L., Louden C., Arleth A., Poste G., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6189-6193.
22. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., Udelson J.E. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am. Heart J. 141:2001;899-907.
23. Ponicke K., Schluter K.D., Heinroth-Hoffmann I., Seyfarth T., Goldberg M., Osten B., Piper H.M., Brodde O.E. Noradrenaline-induced increase in protein synthesis in adult rat cardiomyocytes: involvement of only alpha1A- adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 364:2001;444-453.
24. Rapacciuolo A., Esposito G., Caron K., Mao L., Thomas S.A., Rockman H.A. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J. Am. Coll. Cardiol. 38:2001;876-882.
25. Salvi S. Protecting the myocardium from ischemic injury: a critical role for alpha(1)-adrenoreceptors? Chest. 119:2001;1242-1249.
26. Seki N., Nagao T., Komori K., Suzuki H. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein. J. Pharmacol. Exp. Ther. 246:1988;1116-1122.
27. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J. Clin. Invest. 72:1983;732-738.
28. Sjaastad I., Schiander I., Sjetnan A., Qvigstad E., Bokenes J., Sandnes D., Osnes J.B., Sejersted O.M., Skomedal T. Increased contribution of alpha1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol. Scand. 177:2003;449-458.
29. Skomedal T., Osnes J.B., Oye I. Competitive blockade of alpha-adrenergic receptors in rat heart by prazosin. Acta Pharm. Toxicol. (Copenhagen). 47:1980;217-222.
30. Skomedal T., Borthne K., Aass H., Geiran O., Osnes J.B. Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J. Pharmacol. Exp. Ther. 280:1997;721-729.
31. Spahn H., Henke W., Langguth P., Schloos J., Mutschler E. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization. Arch. Pharm. (Weinh.). 323:1990;465-469.
32. Sponer G., Strein K., Bartsch W., Muller-Beckmann B. Vasodilatory action of carvedilol. J. Cardiovasc. Pharmacol. 19(Suppl. 1):1992;S5-S11.
33. Steinfath M., Chen Y.Y., Lavicky J., Magnussen O., Nose M., Rosswag S., Schmitz W., Scholz H. Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br. J. Pharmacol. 107:1992;185-188.
34. Terzic A., Puceat M., Vassort G., Vogel S.M. Cardiac alpha 1-adrenoceptors: an overview. Pharmacol. Rev. 45:1993;147-175.
35. Yang M., Verfurth F., Buscher R., Michel M.C. Is alpha1D-adrenoceptor protein detectable in rat tissues? Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;438-446.
36. Yoshikawa T., Port J.D., Asano K., Chidiak P., Bouvier M., Dutcher D., Roden R.L., Minobe W., Tremmel K.D., Bristow M.R. Cardiac adrenergic receptor effects of carvedilol. Eur. Heart J. 17(Suppl. B):1996;8-16.
37. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:1992;92-98.